Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
Shionogi’s Medicon (dextromethorphan) and Kyorin Pharmaceutical’s Mucodyne (carbocysteine) are on the list of drugs covered by the health ministry’s recent supply boost request, an emergency step aimed to counter the growing shortage of antitussives and expectorants, the companies told Jiho.…
To read the full story
Related Article
- Shionogi CEO Requests Higher Price for Medicon
November 22, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Shionogi Sees 60% Ramp-Up in Medicon Output in FY2023
February 2, 2024
- Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
December 15, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
- JMA Survey Finds Large Gap between Actual Drug Shortage, Industry Poll
October 11, 2023
BUSINESS
- Japan’s 1st Xolair Biosimilar Finally Set for December Launch after Delays
October 23, 2026
- PHP Security Flaws Trigger Website Shutdowns Across Japan Pharma Sector
October 23, 2026
- Enhertu Snares China Approval for HER2 Positive Solid Tumors
October 23, 2026
- Nxera Seeks South Korean Approval for DMD Drug Vamorolone
October 23, 2026
- Vital KSK Warns of Possible Email Address Leak via External Mail Provider
October 23, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…